Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

COVID-19: Are Experimental Drugs a Cure or Cause?

Author(s): Bensu Karahalil* and Aylin Elkama

Volume 17, Issue 2, 2022

Published on: 11 March, 2022

Page: [83 - 89] Pages: 7

DOI: 10.2174/1574886316666210727150127

Price: $65

Abstract

Background: Coronavirus disease 2019 (COVID-19) is a new strain of coronavirus. It is characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has quickly influenced all over the world since it spreads easily. Common symptoms are fever, cough, difficulty in breathing and muscle aches. Despite the urgent need to find an effective antiviral treatment, already available agents are being used alone or in combination all over the world. At the beginning of the pandemic, death rates of infection caused by COVID-19 are high but “is COVID-19 responsible for all deaths?”, or “are there any contributions of the frequently used drugs in this period to these deaths?” Surely herd immunity plays a major role and has contributed to the decline in mortality rates. Meanwhile, it is kept in mind that due to safety concerns, changes have also been made in the dosage and combined use of frequently used drugs.

Objective: In this review, answers to two questions above and the safety of treatments, toxicities of agents involving chloroquine, hydroxychloroquine, remdesivir, favipiravir, lopiravir/ritonavir, sarilumab, tocilizumab, siltuximab, corticosteroids and bromhexine which are the most frequently used in Turkey and all over the world will be summarized.

Conclusion: Among these drugs, favipiravir seems the most promising drug due to more tolerable adverse effects. More clinical trials with large sample sizes are needed to find the most effective and safe drug for COVID-19 treatment.

Keywords: COVID-19, antiviral drugs, immunosuppressant, cytokines, efficacy, safety concerns.

« Previous Next »
Graphical Abstract

[1]
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5(4): 536-44.
[http://dx.doi.org/10.1038/s41564-020-0695-z] [PMID: 32123347]
[2]
Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chin Med Assoc 2020; 83(3): 217-20.
[http://dx.doi.org/10.1097/JCMA.0000000000000270] [PMID: 32134861]
[3]
Ningthoujam R. COVID 19 can spread through breathing, talking, study estimates. Curr Med Res Pract 2020. [Ahead of Print].
[4]
Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6: 16. [eCollection.].
[http://dx.doi.org/10.1038/s41421-020-0156-0]
[5]
Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci 2020; 50(SI-1): 611-9.
[http://dx.doi.org/10.3906/sag-2004-145] [PMID: 32293834]
[6]
Cohen P, Blau J. Coronavirus disease 2019 (COVID-19): Outpatient evaluation and management in adults Eds: Kunins L, Bloom A, Section Eds: Elmore JG. Literature review current through: May 21, 2020. 2020. Available from:https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-outpatient-evaluation-and-management-in-adults Accessed May 23, 2020.
[7]
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer 2018; 6(1): 56.
[http://dx.doi.org/10.1186/s40425-018-0343-9] [PMID: 29907163]
[8]
CORIMUNO-19-tocilizumab trial-toci (CORIMUNO-TOCI) Available from:https://clinicaltrials.gov/ct2/show/NCT04331808 Accessed May 20, 2020.
[9]
NIH. National institute on health. What is new in the guideline. Available from:https://www.COVID-19treatmentguidelines.nih.gov/whats-new/ Accessed May 20, 2020.
[10]
Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect 2020; 80(6): e14-8.
[http://dx.doi.org/10.1016/j.jinf.2020.03.005] [PMID: 32171866]
[11]
Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 2020; 14(3): 241-6.
[http://dx.doi.org/10.1016/j.dsx.2020.03.011] [PMID: 32247211]
[12]
Willis R, Seif AM, McGwin G Jr, et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: Data from LUMINA (LXXV), a multiethnic US cohort. Lupus 2012; 21(8): 830-5.
[http://dx.doi.org/10.1177/0961203312437270] [PMID: 22343096]
[13]
Medscape 2020. Available from:https://www.medscape.com/answers/2500114-197458/what-are-the-roles-of-hydroxychloroquine-and-chloroquine-in-the-treatment-of-coronavirus-disease-2019-COVID-19 Accessed May 20, 2020.
[14]
Lane JCE, Weaver J, Kosta K. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: A multinational, network cohort and self-controlled case series study. Med Rxiv 2020.
[15]
Borba MGS, de Almeida Val F, Sampaio VS, et al. CloroCovid-19 Team. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCOVID-19 Study). Med Rxiv 2020.
[16]
EMA. European Medicines Agency COVID-19: Reminder of risk of serious side effects with chloroquine and hydroxychloroquine. 2020. Available from:https://www.ema.europa.eu/en/news/COVID-19-reminder-risk-serious-side-effects-chloroquine-hydroxychloroquineAccessed April 23, 2020.
[17]
ClinicalTrials. NIH. USA National Library of Medicine. Available from:https://www.clinicaltrials.gov/ Accessed August 12, 2020.
[18]
Coronavirus Treatment Acceleration Program. Available from:https://www.fda.gov/drugs/coronavirus-COVID-19-drugs/coronavirus-treatment-acceleration-program-ctap Accessed May 15, 2020.
[19]
Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020; 18(7): 1738-42. [Online ahead of print.].
[http://dx.doi.org/10.1111/jth.14850] [PMID: 32302438]
[20]
Gozzo L, Viale P, Longo L, Vitale DC, Drago F. The potential role of heparin in patients with COVID-19: Beyond the anticoagulant effect. A review. Front Pharmacol 2020; 11: 1307.
[http://dx.doi.org/10.3389/fphar.2020.01307] [PMID: 32973526]
[21]
EUA Fact Sheet. European University Association Available from:https://www.gilead.com/-/media/files/pdfs/remdesivir/eua- fact-sheet-for-hcps_01may2020.pdf Accessed May 1, 2020.
[22]
Remdesivir EMA. European Medicines Agency Available from:https://www.ema.europa.eu/en/documents/other/summary- compassionate-use-remdesivir-gilead_en.pdf Accessed May 3, 2020.
[23]
Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India 2020; 76(4): 370-6.
[http://dx.doi.org/10.1016/j.mjafi.2020.08.004] [PMID: 32895599]
[24]
Osborne V, Davies M, Lane S, et al. Lopinavir-Ritonavir in the treatment of COVID-19: A dynamic systematic benefit-risk assessment. Drug Saf 2020; 43(8): 809-21.
[http://dx.doi.org/10.1007/s40264-020-00966-9] [PMID: 32578156]
[25]
Mora-Rillo M, Arsuaga M, Ramírez-Olivencia G, et al. Acute respiratory distress syndrome after convalescent plasma use: Treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir Med 2015; 3(7): 554-62.
[http://dx.doi.org/10.1016/S2213-2600(15)00180-0] [PMID: 26041403]
[26]
Chun S, Chung CR, Ha YE, et al. Possible transfusion-related acute lung injury following convalescent plasma transfusion in a patient with middle east respiratory syndrome. Ann Lab Med 2016; 36(4): 393-5.
[http://dx.doi.org/10.3343/alm.2016.36.4.393] [PMID: 27139619]
[27]
Tiberghien P, de Lambalerie X, Morel P. Collecting and evaluating convalescent plasma for COVID-19 treatment: Why and how. VoxSnaguinis 2020. Available from:http://www.sah.org.ar/pdf/COVID-19/vox.12926.pdf
[28]
Sanofi and regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19. Available from:http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19 Accessed May 11, 2020.
[29]
Köhler BM, Günther J, Kaudewitz D, Lorenz HM. Current therapeutic options in the treatment of rheumatoid arthritis. J Clin Med 2019; 8(7): 938.
[http://dx.doi.org/10.3390/jcm8070938] [PMID: 31261785]
[30]
DrugBank. Siltuximab Available from:https://www.drugbank.ca/drugs/DB09036 Accessed May 3, 2020.
[31]
Product Monograph. Product monograph including patient medication information SYLVANT® siltuximab for injection. 2018. Available from:https://www.janssen.com/canada/system/files/prod_files/draft/sylvant_cpm_1.pdf Accessed May 5, 2020.
[32]
EMA. European Medicines Agency, Slyvant INN-Sultiximab. Annex I Summary of product characteristics. Available from:https://www.ema.europa.eu/en/documents/product-information/sylvant-epar-product-information_en.pdf Accessed April 28, 2020.
[33]
Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B. Tocilizumab (Actemra). Hum Vaccin Immunother 2017; 13(9): 1972-88.
[http://dx.doi.org/10.1080/21645515.2017.1316909] [PMID: 28841363]
[34]
DrugBank. Tocilisumab. Available from:https://www.drugbank.ca/drugs/DB06273 Accessed May 11, 2020.
[35]
WHO. World Health Organization, Corticosteroids for COVID-19. Living Guidance 2020.
[36]
Hazbun ME, Faust AC, Ortegon AL, et al. The combination of tocilizumab and methylprednisolone along with initial lung recruitment strategy in coronavirus disease 2019 patients requiring mechanical ventilation: A series of 21 consecutive cases. Crit Care Explor 2020; 2(6): e0145.
[http://dx.doi.org/10.1097/CCE.0000000000000145] [PMID: 32696008]
[37]
Depfenhart M, de Villiers D, Lemperle G, Meyer M, Di Somma S. Potential new treatment strategies for COVID-19: Is there a role for bromhexine as add-on therapy? Intern Emerg Med 2020; 15(5): 801-12.
[http://dx.doi.org/10.1007/s11739-020-02383-3] [PMID: 32458206]
[38]
Ansarin K, Tolouian R, Ardalan M, et al. Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial. Bioimpacts 2020; 10(4): 209-15.
[http://dx.doi.org/10.34172/bi.2020.27] [PMID: 32983936]

Rights & Permissions Print Cite
Article Metrics
49
1
© 2024 Bentham Science Publishers | Privacy Policy